Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv...(products and pricing the timely developm...),Health

                    FOREST LABORATORIES, INC. AND SUBSIDIARIES
                        CONSOLIDATED STATEMENTS OF INCOME


                                        THREE MONTHS         TWELVE MONTHS
                                       ENDED MARCH 31       ENDED MARCH 31
                                      2009      2008       2009       2008
                                   (In thousands, except per share amounts)

    Revenues:
      Net sales                    $896,726  $898,703 $3,636,055 $3,501,802
      Contract revenue               55,203    60,105    209,000    216,500

      Interest income                12,751    31,148     74,409    108,680

      Other income                      797       897      3,318      9,347

    Net revenues                    965,477   990,853  3,922,782  3,836,329


    Costs and expenses:
      Cost of goods sold            207,684   210,376    816,680    800,114
      Selling, general and
       Administrative               515,090   327,426  1,474,274  1,154,845
    Research and development        123,774   255,081    661,294    670,973
                                    846,548   792,883  2,952,248  2,625,932

    Income before

    income tax expense              118,929   197,970    970,534  1,210,397

      Income tax expense             26,166    25,200    202,791    242,464

    Net income                      $92,763  $172,770   $767,743   $967,933


    Net income per share:
      Basic                           $0.31     $0.55      $2.53      $3.08
      Diluted                         $0.31     $0.55      $2.52      $3.06


    Weighted average number of
     shares outstanding:
      Basic                     
'/>"/>
SOURCE  Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 
Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees